Johnson & Johnson Proposes $5.5 Billion Talc Settlement
Johnson & Johnson has announced a proposed $5.5 billion settlement to resolve approximately 76,000 remaining U.S. lawsuits alleging that its talcum powder products, including Johnson’s Baby Powder, caused ovarian cancer.
The agreement covers claims consolidated in the federal multidistrict litigation in New Jersey as well as related cases in state courts, representing nearly all outstanding ovarian cancer claims against the company. It is conditioned on acceptance by at least 95 percent of eligible claimants.
Johnson & Johnson has committed $5.5 billion in total, with an initial payment of no more than $3 billion scheduled for 2027 and additional payments not due before 2028. The settlement is structured as per-claim payments under a tiered system and is uncapped, meaning the ultimate cost could rise depending on participation.
Erik Haas, Johnson & Johnson’s worldwide vice president of litigation, said the company remained confident it would have prevailed in further litigation, as it has in the vast majority of cases tried to date. “This resolution allows the company to put this matter behind it and remain focused on its mission to develop medicines and devices that save lives,” Haas said. The company has long claimed that its talc products are safe, do not contain asbestos and do not cause cancer. It discontinued sales of talc-based baby powder in the United States and Canada in 2020 and worldwide in 2023, switching to a cornstarch-based formula.
Plaintiffs’ attorneys described the agreement as a significant step forward after years of legal battles and three failed attempts by Johnson & Johnson subsidiaries to resolve the claims through bankruptcy. Christopher Seeger, a lead negotiator representing thousands of claimants, called it “a fair measure of long-delayed justice.” He noted that many women and families had waited more than a decade, with some plaintiffs not living to see resolution. Compensation will be determined through a transparent, criteria-based grid designed to deliver payments relatively quickly compared with prior proposals.
The announcement follows a July 22, 2026, order from the MDL court in which U.S. Magistrate Judge Rukhsanah Singh directed plaintiffs to show cause why remaining claims should not be dismissed due to challenges in proving specific causation. Plaintiffs had withdrawn key expert witnesses in certain bellwether cases. Johnson & Johnson has prevailed in the large majority of ovarian cancer trials to date, though juries have also awarded substantial verdicts against the company in individual cases over the years.
The company had previously resolved the bulk of separate claims linking its talc products to mesothelioma, along with state consumer protection actions and supplier disputes. The current proposal applies only to existing ovarian cancer claims and does not bar future lawsuits. Related litigation continues abroad, including a large case in the United Kingdom.
The litigation has spanned more than 15 years and plaintiffs have alleged that talc used for genital hygiene increased ovarian cancer risk, with some claims focusing on alleged asbestos contamination. Independent research and regulatory reviews have produced varying assessments of any causal link. Stock reaction to the news was modestly positive in early trading.
If the 95 percent participation threshold is met (a process expected to take several months), the settlement would provide financial closure for tens of thousands of claimants while allowing Johnson & Johnson to remove a major source of legal uncertainty.
